Skip to main content
Top
Published in: Strahlentherapie und Onkologie 5/2016

01-05-2016 | Literatur kommentiert

Ist beim diffus großzelligen B‑Zell-Lymphom im frühen Stadium nach der Chemotherapie eine konsolidierende Strahlentherapie erforderlich?

Author: Prof. Dr. med. Carsten Nieder

Published in: Strahlentherapie und Onkologie | Issue 5/2016

Login to get access

Auszug

Ob in frühen Stadien eines diffus großzelligen B‑Zell-Lymphoms eine konsolidierende Strahlentherapie (RT) die Ergebnisse einer alleinigen Chemotherapie verbessert, ist nicht abschließend geklärt. Wie in der hier diskutierten Studie referiert wird, existieren Richtlinien (NCCN, ESMO) in denen beide Optionen akzeptiert werden [1]. …
Literature
1.
go back to reference Vargo JA, Gill BS, Balasubramani GK, Beriwal S (2015) Treatment selection and survival outcomes in early-stage diffuse large B‑cell lymphoma: Do we still need consolidative radiotherapy? J Clin Oncol 33:3710–3717CrossRefPubMed Vargo JA, Gill BS, Balasubramani GK, Beriwal S (2015) Treatment selection and survival outcomes in early-stage diffuse large B‑cell lymphoma: Do we still need consolidative radiotherapy? J Clin Oncol 33:3710–3717CrossRefPubMed
2.
go back to reference Longo DL (2015) Combined-modality therapy for early-stage diffuse large B‑cell lymphoma: Knowing when to quit. J Clin Oncol 33:3684–3685CrossRefPubMed Longo DL (2015) Combined-modality therapy for early-stage diffuse large B‑cell lymphoma: Knowing when to quit. J Clin Oncol 33:3684–3685CrossRefPubMed
3.
go back to reference Maurer MJ, Jais JP, Ghesquières H et al (2015) Personalized risk prediction for event-free survival at 24 months in patients with diffuse large B‑cell lymphoma. Am J Hematol 2016;91:179–184. doi:10.1002/ajh.24223CrossRefPubMed Maurer MJ, Jais JP, Ghesquières H et al (2015) Personalized risk prediction for event-free survival at 24 months in patients with diffuse large B‑cell lymphoma. Am J Hematol 2016;91:179–184. doi:10.1002/ajh.24223CrossRefPubMed
4.
go back to reference Ghesquieres H, Slager SL, Jardin F et al (2015) Genome-wide association study of event-free survival in diffuse large B‑cell lymphoma treated with immunochemotherapy. J Clin Oncol 33:3930–3937CrossRefPubMed Ghesquieres H, Slager SL, Jardin F et al (2015) Genome-wide association study of event-free survival in diffuse large B‑cell lymphoma treated with immunochemotherapy. J Clin Oncol 33:3930–3937CrossRefPubMed
6.
go back to reference Mehta-Shah N, Younes A (2015) Novel targeted therapies in diffuse large B‑cell lymphoma. Semin Hematol 52:126–137CrossRefPubMed Mehta-Shah N, Younes A (2015) Novel targeted therapies in diffuse large B‑cell lymphoma. Semin Hematol 52:126–137CrossRefPubMed
7.
go back to reference Bachy E, Salles G (2015) Treatment approach to newly diagnosed diffuse large B‑cell lymphoma. Semin Hematol 52:107–118CrossRefPubMed Bachy E, Salles G (2015) Treatment approach to newly diagnosed diffuse large B‑cell lymphoma. Semin Hematol 52:107–118CrossRefPubMed
Metadata
Title
Ist beim diffus großzelligen B‑Zell-Lymphom im frühen Stadium nach der Chemotherapie eine konsolidierende Strahlentherapie erforderlich?
Author
Prof. Dr. med. Carsten Nieder
Publication date
01-05-2016
Publisher
Springer Berlin Heidelberg
Published in
Strahlentherapie und Onkologie / Issue 5/2016
Print ISSN: 0179-7158
Electronic ISSN: 1439-099X
DOI
https://doi.org/10.1007/s00066-016-0967-y

Other articles of this Issue 5/2016

Strahlentherapie und Onkologie 5/2016 Go to the issue